SM
BCTX

Sabby Management’s Briacell Therapeutics BCTX Stock Holding History

Sabby Management’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2
Closed -$99.8K – 43
2024
Q1 		$99.8K Hold
2
– – 0.06% 32
2023
Q4 		$197K Buy
+2
New +$1.44K 0.2% 24

Other funds holding BCTX

CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
LCM
LuminArx Capital Management New York $136M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Sabby Management's BCTX Position: Q1 2026 in Review

Sabby Management opened a new position in Briacell Therapeutics (BCTX) in Q1 2026: 73,915 shares worth $310K. The stake represents 0.69% of the portfolio and ranks #11 among its holdings. This is a return to the name: Sabby Management previously reported a position in BCTX as recently as Q2 2025.

Sabby Management first reported a position in BCTX in Q1 2021 and has held it in 9 quarters since. The position peaked at $1.04M in Q2 2021. 16 funds tracked by Wall St. Rank hold BCTX as of Q1 2026.

  • Sabby Management held 73,915 shares of Briacell Therapeutics worth $310K as of Q1 2026.
  • Briacell Therapeutics was a new Sabby Management position in Q1 2026.
  • Briacell Therapeutics made up 0.69% of Sabby Management's portfolio in Q1 2026, its #11 holding.
  • Sabby Management first reported a position in Briacell Therapeutics in Q1 2021 and has held it in 9 quarters since.
  • Sabby Management's Briacell Therapeutics position peaked at $1.04M in Q2 2021.
  • 16 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2026.

Based on Sabby Management's 13F filing for Q1 2026, filed 15 May 2026.